Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Morepen LaboratoriesNSE:MOREPENLAB -1.36%74 Interest Coverage is 15.32 as of Jun. 2026, which is 20% below its 10-year median of 19.27. GuruFocus rates NSE:MOREPENLAB with a GF Score™ of 74/100 and a GF Value™ of ₹50.28 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 683 Drug Manufacturers companies, Morepen Laboratories ranks worse than 68.67% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Morepen Laboratories's
Operating Income
for the
three
months ended in Jun. 2026 was ₹742 Mil. Morepen Laboratories's Interest Expense for the
three
months ended in Jun. 2026 was ₹-48 Mil.
Morepen Laboratories's interest coverage for the quarter that ended in Jun. 2026 was 15.32.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Morepen Laboratories's Interest Coverage or its related term are showing as below:
NSE:MOREPENLAB'
s Interest Coverage Range Over the Past 10 Years
Min: 3.88 Med: 19.27 Max: 67.92
Current: 5.43
NSE:MOREPENLAB's Interest Coverage is ranked worse than 68.67% of 683
companies
in the Drug Manufacturers industry
Industry Median: 12.78
vs NSE:MOREPENLAB: 5.43
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Morepen Laboratories Interest Coverage Related Terms
Morepen Laboratories Interest Coverage Historical Data
* Premium members only.
The historical data trend for Morepen Laboratories's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
NSE:MOREPENLAB vs ZTS: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Morepen Laboratories's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Morepen Laboratories Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Morepen Laboratories's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Morepen Laboratories's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Morepen Laboratories (NSE:MOREPENLAB) has a Interest Coverage of 15.32 as of Jun. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Morepen Laboratories and its competitors. This is 20% below median its historical median of 19.27. Over the past decade, Morepen Laboratories' Interest Coverage has ranged from 3.88 to 67.92. According to the industry distribution chart, Morepen Laboratories ranks #469 out of 683 companies in the Drug Manufacturers industry, placing it in the top 68.7%.
Is Morepen Laboratories' Interest Coverage too high?
Morepen Laboratories' current Interest Coverage of 15.32 is 20% below median its 10-year median of 19.27. Over the past 10 years, this metric has ranged from a low of 3.88 to a high of 67.92. The Drug Manufacturers industry median Interest Coverage is 12.78. Morepen Laboratories' value of 15.32 is 19.9% above this industry median. Based on the distribution chart, Morepen Laboratories ranks #469 out of 683 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Morepen Laboratories has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Morepen Laboratories' Interest Coverage compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Morepen Laboratories ranks #469 out of 683 companies for Interest Coverage. This places Morepen Laboratories in the lower half of its industry. The industry median Interest Coverage is 12.78. Morepen Laboratories' value of 15.32 is 19.9% above this benchmark. Historically, Morepen Laboratories' own Interest Coverage has ranged from 3.88 to 67.92 over the past decade. While the company's 10-year median is 19.27 vs. the industry median of 12.78, Morepen Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.78, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Morepen Laboratories's current Interest Coverage of 15.32 is 19.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Morepen Laboratories and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Morepen Laboratories's current Interest Coverage is 15.32, which is 20% below median its own 10-year median of 19.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Morepen Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Morepen Laboratories (NSE:MOREPENLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹50.28, compared to a current price of ₹79.16 — trading 57.4% above its estimated fair value. The current Interest Coverage is 15.32, which is 20% below median its 10-year median of 19.27 and 19.9% above the Drug Manufacturers industry median of 12.78. Morepen Laboratories' overall GF Score™ is 74/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Morepen Laboratories (NSE:MOREPENLAB), the current Interest Coverage is 15.32 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Morepen Laboratories (NSE:MOREPENLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Morepen Laboratories stock appears to be overvalued.
The current stock price of ₹79.16 is trading 57.4% above its estimated GF Value™ of ₹50.28.
GuruFocus considers Morepen Laboratories to be Significantly Overvalued.
Key valuation signals for NSE:MOREPENLAB:
Interest Coverage: 15.32 (20% below median its 10-year median of 19.27)
GF Value™: ₹50.28 vs. price of ₹79.16 (57.4% above fair value)
Industry Position: 19.9% above the Drug Manufacturers median (#469 of 683)
No single metric tells the full story. See the NSE:MOREPENLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Morepen Laboratories Ltd is in the business of manufacturing, producing, developing, and marketing various Active Pharmaceutical Ingredients (APIs), branded and generic formulations, and also Home Health products. Some of the products offered by the company include various drug formulations, APIs, digital thermometers, heat belts, pulse oximeters, nutritional tablets, pain sprays, and others. The company operates in a single segment namely, Pharmaceuticals. Geographically, the company derives maximum revenue from India and the rest from the United States of America, and the Rest of the world.
74GF Score
Get the complete analysis for NSE:MOREPENLAB
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MOREPENLAB has been successfully added to your 
